Guess Who Picked Blue Bird Corp (NASDAQ:BLBD) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Blue Bird Corp (NASDAQ:BLBD) reported that Coliseum Capital has picked up 2,241,426 of common stock as of 2017-03-22.
The acquisition brings the aggregate amount owned by Coliseum Capital to a total of 2,241,426 representing a 9.5% stake in the company.
For those not familiar with the company, Hennessy Capital LLC is an alternative investment platform focused on industrial sector opportunities utilizing unique and proprietary investment vehicles and strategies.
A glance at Blue Bird Corp (NASDAQ:BLBD)’s key stats reveals a current market capitalization of 375.39 Million based on 23.03 Million shares outstanding and a price at last close of $16.30 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-06-08, Asp picked up 5,000,0000 at a purchase price of $11.00. This brings their total holding to 12,000,000 as of the date of the filing.
On the sell side, the most recent transaction saw Coliseum unload 50,000 shares at a sale price of $17.00. This brings their total holding to 1,122,615.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Blue Bird Corp (NASDAQ:BLBD) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Therapeuticsmd Inc. (NYSEMKT:TXMD) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Therapeuticsmd Inc. (NYSEMKT:TXMD) reported that Smith Robert J has picked up 12,157,505 of common stock as of 2017-03-22.
The acquisition brings the aggregate amount owned by Smith Robert J to a total of 12,157,505 representing a 6.15% stake in the company.
For those not familiar with the company, TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
A glance at Therapeuticsmd Inc. (NYSEMKT:TXMD)’s key stats reveals a current market capitalization of 1.22 Billion based on 197.52 Million shares outstanding and a price at last close of $6.42 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-11, Collins picked up 16,000 at a purchase price of $6.23. This brings their total holding to 36,000 as of the date of the filing.
On the sell side, the most recent transaction saw Krassan unload 30,000 shares at a sale price of $8.18. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Therapeuticsmd Inc. (NYSEMKT:TXMD) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Red Robin Gourmet Burgers Inc. (NASDAQ:RRGB) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Red Robin Gourmet Burgers Inc. (NASDAQ:RRGB) reported that Integrated Core Strategies (us) Llc. has picked up 535,489 of common stock as of 2017-03-22.
The acquisition brings the aggregate amount owned by Integrated Core Strategies (us) Llc. to a total of 535,489 representing a 4.2% stake in the company.
For those not familiar with the company, Red Robin Gourmet Burgers, Inc., together with its subsidiaries, primarily develops, operates, and franchises full-service restaurants in North America and focuses on serving selection of gourmet burgers. The Company’s menu features a line of gourmet burgers, which it makes from ground beef, as well as its line of Red’s Tavern Double Burgers and its Red Robin’s line of half-pound Angus beef burgers with various toppings. The Company also offers burgers made from chicken breasts, fish fillets, turkey patties, as well as vegetarian and vegan options. The Company offered a selection of buns, including ciabatta, gluten free, sesame, onion, whole grain, jalapeno and lettuce wraps a range of toppings, including fresh guacamole, house made barbeque sauces, aiolis, grilled pineapple, crispy onion straws, sauteed mushrooms, fried jalapenos, bruschetta salsa, coleslaw, eight different cheese choices and a fried egg, as of December 25, 2016.
A glance at Red Robin Gourmet Burgers Inc. (NASDAQ:RRGB)’s key stats reveals a current market capitalization of 681.76 Million based on 12.86 Million shares outstanding and a price at last close of $53.70 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-02, Connors picked up 1,100 at a purchase price of $47.90. This brings their total holding to 4,115 as of the date of the filing.
On the sell side, the most recent transaction saw Howell unload 3,000 shares at a sale price of $55.33. This brings their total holding to 23,068.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Red Robin Gourmet Burgers Inc. (NASDAQ:RRGB) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Voce Capital is Buying Cutera Inc. (NASDAQ:CUTR) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Cutera Inc. (NASDAQ:CUTR) reported that Voce Capital has picked up 477,031 of common stock as of 2017-03-22.
The acquisition brings the aggregate amount owned by Voce Capital to a total of 477,031 representing a 3.4% stake in the company.
For those not familiar with the company, Cutera, Inc. is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers. Each of its laser and other energy-based platforms consists of one or more hand pieces and a console that incorporates a universal graphical user interface, a laser or other energy-based module, control system software and high voltage electronics. enlighten is a dual wavelength (1,064 nanometer + 532 nanometer) and dual pulse duration (750 picosecond (ps) and 2 nanosecond (ns)) laser system. excel V is a vascular and benign pigmented lesion treatment platform designed for the core-market of dermatologists and plastic surgeons.
A glance at Cutera Inc. (NASDAQ:CUTR)’s key stats reveals a current market capitalization of 271.31 Million based on 13.87 Million shares outstanding and a price at last close of $20.30 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2012-08-21, Connors picked up 7,000 at a purchase price of $7.35. This brings their total holding to 610,971 as of the date of the filing.
On the sell side, the most recent transaction saw Plants unload 250,000 shares at a sale price of $20.25. This brings their total holding to 477,031.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Cutera Inc. (NASDAQ:CUTR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Bb Biotech Ag Picked Radius Health Inc. (NASDAQ:RDUS) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Radius Health Inc. (NASDAQ:RDUS) reported that Bb Biotech Ag has picked up 4,718,922 of common stock as of 2017-03-22.
The acquisition brings the aggregate amount owned by Bb Biotech Ag to a total of 4,718,922 representing a 10.9% stake in the company.
For those not familiar with the company, Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
A glance at Radius Health Inc. (NASDAQ:RDUS)’s key stats reveals a current market capitalization of 1.48 Billion based on 43.19 Million shares outstanding and a price at last close of $36.87 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-21, Biotech picked up 50,000 at a purchase price of $35.83. This brings their total holding to 4,540,399 as of the date of the filing.
On the sell side, the most recent transaction saw Ward unload 25,000 shares at a sale price of $62.77. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Radius Health Inc. (NASDAQ:RDUS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
First National Corp (OTCMKTS:FXNC) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), First National Corp (OTCMKTS:FXNC) reported that First National Corp Employee Stock Ownership Plan has picked up 247,283 of common stock as of 2017-03-22.
The acquisition brings the aggregate amount owned by First National Corp Employee Stock Ownership Plan to a total of 247,283 representing a 5.0% stake in the company.
For those not familiar with the company, First National Corporation is a bank holding company of First Bank (the Bank). The Bank is a commercial bank, which provides loan, deposit, wealth management and other products and services in the Shenandoah Valley and central regions of Virginia. Loan products and services include personal loans, residential mortgages, home equity loans and commercial loans. Deposit products and services include checking, savings, and negotiable order of withdrawal (NOW) accounts, money market accounts, individual retirement accounts, certificates of deposit and cash management accounts. The Bank offers other services, including Internet banking, mobile banking, remote deposit capture and other traditional banking services. The Bank’s wealth management department offers estate planning, investment management of assets, trustee under an agreement, trustee under a will, individual retirement accounts and estate settlement.
A glance at First National Corp (OTCMKTS:FXNC)’s key stats reveals a current market capitalization of 69.95 Million based on 4.93 Million shares outstanding and a price at last close of $14.20 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-20, Brannock picked up 10 at a purchase price of $14.25. This brings their total holding to 502 as of the date of the filing.
On the sell side, the most recent transaction saw Smith unload 245,124 shares at a sale price of $6.20. This brings their total holding to 152,655.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on First National Corp (OTCMKTS:FXNC) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
New IPO Stock Therapix BioSciences (NASDAQ:TRPX) Is Undervalued Compared To Peers – But Not For Long
Some of the biggest biotechnology winners of 2017 so far are cannabis stocks. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a $3 billion pharmaceutical cannabis company and probably the most well known company in this subsector of healthcare, is up around 7% since the start of the year. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a $250 million company, is up 22% year to date and close to 80% across the last twelve months.
Both of these companies have something in common – they are working to bring synthetic cannabinoids through clinical development in the US to treat conditions with a high unmet need, and in turn, a large potential market.
While we expect both to continue to appreciate throughout 2017 and beyond, as their respective pipelines mature towards commercialization, the already registered advance in each limits the upside somewhat.
There’s another company, however, with a very similar development strategy (synthetic cannabinoids) to those of GW Pharmaceuticals and Zynerba, but which has yet to benefit from the upside revaluation described above.
The company is Therapix BioSciences (NASDAQ:TRPX) and the reason it’s not yet revalued in line with its strategic peers is simple – it conducted its IPO today.
Before we get into the company, a bit of background on the space.
The medicinal benefits of cannabis are well established in a large number of different diseases and conditions. There’s evidence to suggest that sufferers of everything from neurodegenerative conditions (Alzheimer’s, dementia, etc.) to pain management to oncology and chemotherapy induced nausea can benefit from cannabis consumption in various forms, and this is the foundation of the medical marijuana industry in the United States. There are some inherent problems with using cannabis to treat these conditions, however, and the primary of these issues are side effects, consumption method and dosing. It’s incredibly difficult to ensure consistent dosing when a patient is smoking cannabis as an administration method. It’s also often undesirable (there are patients who don’t want to smoke) and creates obvious side effects, many of which are unwanted – cerebral high, respiratory issues, cancer, etc.
Synthetic cannabinoids are the focus of the above discussed companies, and many more, because they allow for the creation of cannabis based therapies, i.e. those that employ cannabinoids, or synthetic versions of cannabinoids, that don’t bring about the unwanted side effects that the natural product might, and can be administered in a controlled, measured format.
With GW Pharmacetucals, it’s a sublingual spray. With Zynerba, it’s a CBD based gel. Other companies, companies like Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX), are developing topical administration, cannabis based creams.
Therapix’s answer is a sublingual tablet.
The company is developing a lead asset called THX-TS01, in a primary indication of Tourette’s syndrome. Tourette’s is a neuropsychiatric disorder that causes twitching, involuntary sounds and noises, blinking, and various other ticks, and the current standard care in the space is drug called haloperidol. It’s only really used in the most severe cases, however, as it brings with it some pretty nasty side effects, and it doesn’t really do anything about the tics side of the condition. Many Tourette’s sufferers use cannabis to ease the physical symptoms, and there’s a growing body of evidence that this is an effective method of treatment and control.
However, as mentioned above, many don’t want to smoke cannabis just to treat their symptoms. They either don’t want the high or don’t want to risk the respiratory and oncologic issues associated with smoking.
This is where THX-TS01 comes in.
The drug is a combination of synthetic THC (the active compound in cannabis) and what’s called PEA. PEA is a natural compound found in many substances (milk, fruits, etc.). It isn’t strictly a cannabinoid, but it shares many properties with cannabinoids, and – and here’s an important point – can enhance the impact of synthetic cannabinoids on the central nervous system (CNS) through what’s called the Entourage Effect, without enhancing its effect on the brain.
This Entourage Effect means Therapix has been able to take a small amount of synthetic THC (an amount not potent enough to bring about the cannabis associated high) and boost its impact on the CNS to a degree where it can improve the physical and tic-related symptoms of Tourette’s syndrome.
That’s the theory, at least, and it’s this theory that the company is out to prove subsequent to today’s IPO.
With both synthetic THC (probably more commonly known as dronabinol in the pharmaceutical space) and PEA already used in other approved drugs, there’s no need for Therapix to carry out preclinical or phase I studies for THX-TS01. Instead the company can take it through a phase II trial, and on succesfull completion of the phase II, directly into a pivotal investigation.
The first of these, the phase II (actually a phase IIa) is already underway, having initiated in December 2016. It’s enrolling at Yale University right now, and 4 out of a planned 20 patients are already on board. The trial should wrap up early third quarter 2017, and the company intends to put out topline in the same quarter. This paves the way for a pivotal trial (likely a phase IIb/III) kicking off before the end of the year.
It’s also eligible for Orphan Designation in the US, and Therapix intends to file for this designation once it has the data form the ongoing phase IIa in hand.
Beyond the Tourette’s indication, Therapix is targeting a host of other conditions, with the next in line being mild cognitive impairment (MCI). This is a bigger market than Tourette’s (although it won’t qualify for Orphan Designation) and Therapix expects to initiate a phase IIa study – the equivalent of the study that’s ongoing in Tourette’s right now – during the third quarter of this year.
With just 3.1 million shares outstanding, this company has a low float and high insider ownership – circa 60% as things stand. The company has $12 million cash, which it expects will carry it through to end 2018. Based on its mid point offering price of $6, the company was expected to hit markets with a market capitalization of $18.6 million.
The company opened at $6.30, and at time of writing, morning US session, is trading at $8.60. Based on the 3.1 million expected outstanding share count, this gives the company a current market capitalization of just $26.6 million – above expected, but still low given Therapix’s underlying operations.
Not only is this a low valuation compared to some of the mid cap players with comparable programs, like the above mentioned Zynerba, but it also falls far short of other cannabis stocks with far less promising, or far less developed, programs.
The above mentioned Cannabics Pharmaceuticals, which we noted above as developing topical administration assets, is pre clinical and has a market capitalization of $330 million. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP), a company working to develop cannabis based oncology therapies, is, again, preclinical, and had a market capitalization of more than $178 million at last close.
Bottom line here is that this is a company that is only valued at its current market capitalization because it’s yet to enjoy the exposure to public market capital in the US that some of its strategic and operational peers have.
Now it’s a NASDAQ company, chances are this discrepancy will quickly disappear.
Guess Who Picked Jpmorgan China Region Fund Inc. (NYSE:JFC) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Jpmorgan China Region Fund Inc. (NYSE:JFC) reported that Bulldog Investors has picked up 669,042 of common stock as of 2017-03-22.
The acquisition brings the aggregate amount owned by Bulldog Investors to a total of 669,042 representing a 10.38% stake in the company.
For those not familiar with the company, JPMorgan China Region Fund, Inc. is a non-diversified closed-end management investment company. The Fund seeks to achieve long-term capital appreciation through investments primarily in equity securities of companies with substantial assets in, or revenues derived from, the People’s Republic of China (China), Hong Kong, Taiwan and Macau, collectively, the China Region. The Fund invests in various industries, including aerospace and defense, airlines, automobiles, banks, beverages, capital markets, chemicals, commercial services and supplies, construction and engineering, diversified consumer services, diversified telecommunication services, healthcare providers and services, hotels, restaurants and leisure, independent power and renewable electricity producers, insurance, Internet software and services, leisure products, machinery, media, food and staples retailing, gas utilities and pharmaceuticals. The Fund’s investment advisor is JF International Management Inc.
A glance at Jpmorgan China Region Fund Inc. (NYSE:JFC)’s key stats reveals a current market capitalization of 115.61 Million based on 6.45 Million shares outstanding and a price at last close of $18.08 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-09-12, Hass picked up 1,000 at a purchase price of $17.75. This brings their total holding to 1,000 as of the date of the filing.
On the sell side, the most recent transaction saw Hass unload 1,000 shares at a sale price of $17.55. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Jpmorgan China Region Fund Inc. (NYSE:JFC) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.